SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival.
作者信息
Nuijten M, Mickisch G
出版信息
Br J Cancer. 2010 Jan 5;102(1):232-3; author reply 234-5. doi: 10.1038/sj.bjc.6605446.
Abstract
摘要
相似文献
1
SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival.一线转移性肾细胞癌治疗中索拉非尼（SUN）对比贝伐单抗（BEV）联合干扰素（IFN）：无证据表明无进展生存期存在统计学显著差异。
Br J Cancer. 2010 Jan 5;102(1):232-3; author reply 234-5. doi: 10.1038/sj.bjc.6605446.
2
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.贝伐珠单抗联合干扰素-α对比舒尼替尼用于意大利肾细胞癌一线治疗的成本最小化分析。
Clin Drug Investig. 2011;31(7):507-17. doi: 10.2165/11590230-000000000-00000.
3
Tolerability of first-line therapy for metastatic renal cell carcinoma.转移性肾细胞癌一线治疗的耐受性
Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26.
4
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.一线转移性肾细胞癌治疗中不良反应管理成本：贝伐珠单抗联合干扰素-α2a 与舒尼替尼比较。
Br J Cancer. 2010 Jan 5;102(1):80-6. doi: 10.1038/sj.bjc.6605417. Epub 2009 Nov 17.
5
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.用于肾细胞癌的新型药物需要新型选择模式来优化一线治疗。
Cancer Treat Rev. 2009 May;35(3):289-96. doi: 10.1016/j.ctrv.2009.01.004. Epub 2009 Feb 15.
6
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.舒尼替尼和贝伐单抗用于转移性肾细胞癌一线治疗：临床疗效的系统评价和间接比较
Br J Cancer. 2009 Jul 21;101(2):238-43. doi: 10.1038/sj.bjc.6605167. Epub 2009 Jun 30.
7
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.对“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合干扰素-α2a与舒尼替尼的比较”的评论
Br J Cancer. 2010 Oct 12;103(8):1307-8; author reply 1309-10. doi: 10.1038/sj.bjc.6605886. Epub 2010 Sep 14.
8
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.已获批的一线抗血管生成和分子靶向治疗药物在治疗低危和中危转移性透明细胞肾细胞癌中的疗效比较
BMC Cancer. 2014 Aug 15;14:592. doi: 10.1186/1471-2407-14-592.
9
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.关于：“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合α-干扰素2a与舒尼替尼的比较”
Br J Cancer. 2010 Mar 30;102(7):1196-7. doi: 10.1038/sj.bjc.6605585. Epub 2010 Feb 23.
10
[First-line therapy of metastatic renal cell carcinoma--update 2009].[转移性肾细胞癌的一线治疗——2009年更新]
Onkologie. 2010;33 Suppl 1:5-9. doi: 10.1159/000265688. Epub 2010 Jan 22.
引用本文的文献
1
Targeted therapy for advanced renal cell carcinoma.晚期肾细胞癌的靶向治疗
Cochrane Database Syst Rev. 2008 Apr 16;2008(2):CD006017. doi: 10.1002/14651858.CD006017.pub2.
本文引用的文献
1
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.舒尼替尼和贝伐单抗用于转移性肾细胞癌一线治疗：临床疗效的系统评价和间接比较
Br J Cancer. 2009 Jul 21;101(2):238-43. doi: 10.1038/sj.bjc.6605167. Epub 2009 Jun 30.
2
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.贝伐单抗联合干扰素α与干扰素α单药治疗转移性肾细胞癌患者的比较：CALGB 90206研究
J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.
3
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.贝伐单抗联合干扰素α-2a治疗转移性肾细胞癌：一项随机、双盲III期试验。
Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7.
4
Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses.间接比较在评估竞争性干预措施疗效方面的有效性：来自已发表的荟萃分析的实证证据。
BMJ. 2003 Mar 1;326(7387):472. doi: 10.1136/bmj.326.7387.472.
5
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.随机对照试验荟萃分析中直接和间接治疗比较的结果。
J Clin Epidemiol. 1997 Jun;50(6):683-91. doi: 10.1016/s0895-4356(97)00049-8.
Zotero 插件